CSI Market
Sign In | Register

Keenova Therapeutics Plc (MNK) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access MNK Annual Income Statement →
This page allows investors to track Keenova Therapeutics Plc's income statement performance across multiple reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
Q1 2026 		(Dec 31 2025) (Sep 26 2025) (Mar 28 2025) (Sep 27 2024)
Revenues
Revenue From Contract With Customer Including Assessed Tax468.30
Total Revenue467.60
Costs & Expenses
Cost of Goods and Services Sold281.00
Gross Profit186.60
Selling, Administration, Marketing210.60
Depreciation & Amortization61.00
Research and Development Expense23.20
Restructuring Charges19.80
Other Operating Expense / -Income0.00
Total operating costs including COS534.60
Operating income / -loss-67.00
Interest Expense0.00
Interest Income-5.40
Net Interest Expense / -Income-5.40
Extinguishment of Debt0.00
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal0.10
Other loss / -income47.10
Total costs & expenses576.30
Income & Taxes
Income / -loss before income taxes-108.70
Income taxes expenses / -benefit4.80
Income after income taxes-113.50
Income / -loss from continuing operations-113.50
Discontinued operations0.00
Net income / -loss-113.50
Income / -loss to shareholder-113.50
EBIT-114.10
EBITD-53.10
EBITDA-53.10
Earnings Per Share
Basic EPS (excl. extra items)-2.87
Extraordinary items0.00
Basic Net EPS-2.87
Basic shares outstanding (Mill. of Units)39.60
Diluted Net EPS-2.87
Diluted average shares (Mill. of Units)39.60
4 historic quarters locked

Sign in to unlock the full Keenova Therapeutics Plc income statement history.

Sign In Create Free Account

About Keenova Therapeutics Plc Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: August 11, 2026
  • Original filing: mnk-20260630.htm

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.